Showing results (241-250 of 457) with videos related to

Sort By:
Pageof 46
British Journal of Cancer|July 7, 2017
Integrating cytokines and angiogenic factors and tumour bulk with selected clinical criteria improves determination of prognosis in advanced renal cell carcinomaA J Zurita, R C Gagnon, Y Liu, et al.
The Oncologist|October 9, 2023
Efficacy and Safety of Darolutamide in Combination With Androgen-Deprivation Therapy and Docetaxel in Black Patients From the Randomized ARASENS TrialNeal D Shore, Maha Hussain, Fred Saad, et al.
World Journal of Urology|August 5, 2016
Second-line treatment for metastatic clear cell renal cell cancer: experts' consensus algorithmsC Rothermundt, J von Rappard, T Eisen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 30, 2021
The Effect of Corticosteroids on Prostate Cancer Outcome Following Treatment with Enzalutamide: A Multivariate Analysis of the Phase III AFFIRM TrialJimmy L Zhao, Karim Fizazi, Fred Saad, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|November 14, 1997
Mugwort and sage (Artemisia) pollen cross-reactivity: ELISA inhibition and immunoblot evaluationR K Katial, F L Lin, W W Stafford, et al.
European Urology|November 8, 2011
Sequencing of agents for metastatic renal cell carcinoma: can we customize therapy?Guru Sonpavde, Toni K Choueiri, Bernard Escudier, et al.
Clinical Genitourinary Cancer|October 12, 2019
COMPARZ Post Hoc Analysis: Characterizing Pazopanib Responders With Advanced Renal Cell CarcinomaCora N Sternberg, Robert J Motzer, Thomas E Hutson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2009
Phase II study of dasatinib in patients with metastatic castration-resistant prostate cancerEvan Y Yu, George Wilding, Edwin Posadas, et al.
ESMO Open|May 13, 2021
SAUL, a single-arm study of atezolizumab for chemotherapy-pretreated locally advanced or metastatic carcinoma of the urinary tract: outcomes by key baseline factors, PD-L1 expression and prior platinum therapyA Bamias, A S Merseburger, Y Loriot, et al.
Future Oncology (London, England)|October 13, 2022
Which traits affect how long patients with advanced prostate cancer live when treated with enzalutamide?Ugo De Giorgi, Maha Hussain, Neal Shore, et al.
Pageof 46